Elsevier’s 2026 Intravenous Medications, 42nd Edition

• o Annual publication prevents users from referencing outdated information. • o 40-year history of impeccable accuracy reinforces the importance of safe IV drug administration. • o Monographs on more than 400 IV drugs offers an impressive breadth of coverage that goes well beyond any comparable drug reference. • o Proven, clinically-optimized page layout keeps all dosage information for each drug on either a single page or a two-page spread to prevent hand contamination by having to turn a page. • o Highlighted Black Box Warnings and relevant content make locating critical information fast and easy. • o Special circumstances in blue-screened text call attention to important circumstances that may not warrant black box warnings. • o Convenient, alphabetical format organizes all drug monographs by generic name, allowing users to find any drug in seconds. • o Dilution and dosage charts within monographs provide quick access to essential clinical information. • o Life stage dosage variances are highlighted for geriatric, pediatric, infant, and neonatal patients.

• o New drug monographs for approximately 10-20 newly approved drugs by the FDA provides readers with the most current drug information. • o Each monograph updated as necessary with new interactions, precautions, alerts, patient teaching instructions, and other need-to-know information. Current information helps nurses feel confident in the accuracy of the information and helps prevent medication dispensing errors

General Dilution Charts (inside front cover and facing page) How to Use This Book Evolve Website Information Format and Content of Intravenous Medications Key to Abbreviations Important IV Therapy Facts Resources IV Drugs [alphabetical drug monographs] Back Matter Appendixes: A. Recommendations for the Safe Use and Handling of Cytotoxic Drugs B. FDA Pregnancy Categories C. U.S. Department of Health and Human Services, National Institutes of Health, and National Cancer Institute Common Terminology Criteria for Adverse Events D. Information for Patients Receiving Immunosuppressive Agents E. Recently Approved Drugs Index

Shelly Rainforth Collins, PharmD, BCGP, President, Drug Information Consultants, Chesapeake, Virginia